Preclinical Efficacy and Intermediate Endpoint Biomarkers
Award Notice Posted
- Solicitation number
- N01CN25002-78
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Awarded
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- HHSN261201200013I_HHSN261201200014I_HHSN261201200015I_HHSN261201200016I
- NAICS code
- 541711 Research and Development in Biotechnology
- PSC
- Not on record
Notice details come from SAM.gov. Updated .
Notice text
2 versions
Update #2 · Latest ·
The purpose of these ID/IQ contracts is to evaluate the efficacy of potential chemopreventive regimens as well as to identifypharmacodynamic and or efficacy biomarkers which will enhance the development of these regimens for clinicaltrials. The studies will include, for example, evaluations of the efficacy of multiple chemopreventive regimens (newagents, altered dosing of agents, combinations of agents, vaccines, altered mechanisms of dosing) in multiple modelsof cancer in rodents. In addition the Contractor may have to examine a wide variety of potential biomarkers. TheContractor shall conduct intermediate endpoint assays in rodent tissues and may perform studies in NCI-suppliedhuman samples examining relevant intermediate endpoints. Task Orders can be either firm fixed-price or cost-reimbursement.
Update #1 ·
RFP N01CN25002-78 entitled "Preclinical Efficacy and Intermediate Endpoint Biomarkers"
Files
Notice history
| Notice | Type | Posted |
|---|---|---|
| This notice | Award Notice | |
| Preclinical Efficacy and Intermediate Endpoint Biomarkers | Award Notice | |
| Preclinical Efficacy and Intermediate Endpoint Biomarkers | Award Notice |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity